However, in comparison to the MET wild‐type group, the median progression‐free survival time in the MET amplification group exhibited a reduction of 123.9 days (from 363.2 days to 239.3 days), thereby indicating that MET amplification serves as an independent risk factor for the survival of patients with EGFR‐mutated NSCLC. This evidence concerns the gene MET and non-small cell lung carcinoma.